Student Research Committee, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Department of Community Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Complement Ther Med. 2023 Jun;74:102952. doi: 10.1016/j.ctim.2023.102952. Epub 2023 May 11.
Liver conditions are major burdens upon health systems around the world. Turmeric /curcumin is believed to possess therapeutic features in ameliorating various metabolic disorders. In this systematic review and meta-analysis of the randomized controlled trials (RCTs), we examined the effect of turmeric/curcumin supplementation on some liver function tests (LFTs).
We comprehensively searched online databases (i.e. PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar) from inception up to October 2022. Final outcomes included aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT). Weighted mean differences (WMDs) were reported. In case of between-study heterogeneity, subgroup analysis was conducted. Non-linear dose-response analysis was carried out to detect the potential effect of dosage and duration. The registration code is CRD42022374871.
Thirty-one RCTs were included in the meta-analysis. Turmeric/curcumin supplementation significantly reduced blood levels of ALT (WMD = -4.09 U/L; 95 % CI = -6.49, -1.70) and AST (WMD = -3.81 U/L; 95 % CI = -5.71, -1.91), but not GGT (WMD: -12.78 U/L; 95 % CI: -28.20, 2.64). These improvements, though statistically significant, do not ensure clinical effectiveness.
It seems that turmeric/curcumin supplementation might be effective in improving AST and ALT levels. However, further clinical trials are needed to examine its effect on GGT. Quality of the evidence across the studies was low for AST and ALT and very low for GGT. Therefore, more studies with high quality are needed to assess this intervention on hepatic health.
肝脏疾病是全球卫生系统的主要负担。姜黄/姜黄素被认为具有改善各种代谢紊乱的治疗特性。在这项对随机对照试验 (RCT) 的系统评价和荟萃分析中,我们检查了姜黄/姜黄素补充剂对一些肝功能测试 (LFT) 的影响。
我们全面搜索了在线数据库(即 PubMed、Scopus、Web of Science、Cochrane Library 和 Google Scholar),从成立到 2022 年 10 月。最终结果包括天冬氨酸氨基转移酶 (AST)、丙氨酸氨基转移酶 (ALT) 和γ-谷氨酰转移酶 (GGT)。报告了加权均数差 (WMD)。如果存在研究间异质性,则进行亚组分析。进行非线性剂量反应分析以检测剂量和持续时间的潜在影响。注册码为 CRD42022374871。
荟萃分析纳入了 31 项 RCT。姜黄/姜黄素补充剂显著降低了 ALT(WMD = -4.09 U/L;95%CI = -6.49, -1.70)和 AST(WMD = -3.81 U/L;95%CI = -5.71, -1.91)的血液水平,但对 GGT 没有影响(WMD:-12.78 U/L;95%CI:-28.20, 2.64)。这些改善虽然具有统计学意义,但并不能确保临床疗效。
姜黄/姜黄素补充剂似乎可以有效改善 AST 和 ALT 水平。然而,需要进一步的临床试验来检查其对 GGT 的影响。对于 AST 和 ALT,研究的证据质量低,对于 GGT,证据质量极低。因此,需要更多高质量的研究来评估这种干预措施对肝脏健康的影响。